07:55 AM EDT, 06/27/2025 (MT Newswires) -- Haleon ( HLN ) said in a regulatory filing Friday it has completed the acquisition of the remaining 12% equity interest in Tianjin TSKF Pharmaceutical, the company's joint venture in China, for 1.62 billion Chinese renminbi ($226.4 million).

According to the company, the deal will allow it to drive category growth in one of the fastest-growing OTC markets globally.

As a result of the transaction, Tianjin TSKF Pharmaceutical is now a wholly-owned subsidiary of Haleon ( HLN ), the company said.